What Is the LifeVest Wearable Defibrillator?

The LifeVest® wearable cardioverter defibrillator (WCD) is a treatment option for patients at risk of sudden cardiac death (SCD) that can offer advanced protection and monitoring as well as improved quality of life.

LifeVest is a wearable defibrillator. Unlike an implantable cardioverter defibrillator (ICD), LifeVest is worn outside the body rather than implanted in the chest. LifeVest is designed to continuously monitor a patient’s heart, detect certain life-threatening rapid heart rhythms, and automatically deliver a treatment shock to restore normal heart rhythm.

The device is designed to alert a patient prior to delivering a treatment shock, and thus allows a conscious patient to delay the treatment. If the patient becomes unconscious, the device is designed to release a Blue™ gel over the therapy electrodes and deliver an electrical shock to restore normal rhythm.

Following a cardiac event, risk of SCD is highest in the first 90 days1,2
1Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581–2588.
2Adabag AS, Therneau TM, Gersh BJ, et al. Sudden death after myocardial infarction. JAMA. Circulation 2008;300(17):2022–2029.

Despite PCI & GDMT, 1 in 20 post-MI (EF≤35%) patients die in the first 90 days3
3Olgin JE, Pletcher MJ, Vittinghoff E, et al. Wearable cardioverter-defibrillator after myocardial infarction. N Engl J Med. 2018;379(13):1205–1215.

SCD accounts for ~50% of mortality following an MI, PCI, or new HF diagnosis (EF≤35%)4,5
4Olgin JE, Pletcher MJ, Vittinghoff E, et al. Wearable cardioverter-defibrillator after myocardial infarction. N Engl J Med. 2018;379(13):1205–1215.
5Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334(21):1349–1355.